Global Antipsychotic Drugs Market report published by Accurize Market Research forecast that the global market is expected to reach $14.5 billion by 2023; growing at a CAGR of 2.1% from 2017 to 2025. By geography, the Asia Pacific and North America are expected to grow at a CAGR of XX% and XX%, respectively, during the forecast period.

Request Sample: https://www.accurizemarketresearch.com/report/antipsychotic-drugs-market/sample-request

The high pervasiveness of schizophrenia, increased drug abuse and over-prescription of drugs to drive the growth of the market

The high pervasiveness of schizophrenia, psychotic ailments increased drug abuse and over-prescription of drugs fuels the demand for the global antipsychotic drugs market. Furthermore, increasing initiatives by government and addiction to antipsychotic drugs also boosts the growth of the market.

Market Segmentation

The global antipsychotic drugs market has been bifurcated on the basis of the mechanism of action, disease indication, and geography. The mechanism of action segment is bifurcated as global antipsychotic drug market, d2 antagonists, d2/5ht2a antagonists, and d2 partial agonists. Disease indication segment is further bifurcated as schizophrenia, bipolar disorder, major depressive disorder, and other disease indications agonists. By geography, the market is segmented into North America, Europe, Asia-Pacific, and Rest of the World (RoW).

Request Customization: https://www.accurizemarketresearch.com/report/antipsychotic-drugs-market/ask-for-customization

Top players in the market

The key players operational in the market includes Acadia Pharmaceuticals Inc., Alembic Pharmaceuticals Ltd., Alexza Pharmaceuticals, Alkermes Plc., Allergan Plc., Apotex, Inc., AstraZeneca Plc., Aurobindo Pharma, Dr. Reddy's Laboratories Ltd., Eli Lilly and Co., and Gedeon Richter Plc., among others.